TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2250 participants.
Also called NCT07052903
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,250 participants
- Sponsor
- Registry
-
NCT07052903 -
2024-519917-72-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, France, Germany, Greece, Hong Kong SAR China, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07052903. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-02 (actual); primary completion 2030-05-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Condition
- Transthyretin Amyloidosis With Cardiomyopathy
- Intervention (Drug)
- Nucresiran
- Intervention (Drug)
- Sterile Normal Saline (0.9% NaCl)
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct07052903- Content hash
ea6fc88e4837d657a966ef2daa89ee92886d2acf7cb440e143a60e5bbd32508c